Timeline

• 1979- Dyadic founded by Mark Emalfarb

• 1980’s – Leading provider of pumice stones for the denim industry

• Early 1990’s – Discovered the C1 microorganism (fungus) in Russia

• 1994 – Began commercial production of industrial enzymes

• 1996 – Began commercial production of industrial enzymes from the C1 fungus

• 2003 – Establishes research and development facility in the Netherlands

• 2004 – Establishes Scientific Advisory Board headed by Dr. Richard Lerner (former head of Scripps Research Institute)

• 2004 – Raises approximately $26 million in private transactions

• 2004 –  Becomes a publicly traded company

• 2005 – Sequences the C1 genome

• 2006 –  Partners with Scripps Florida to annotate the C1 genome

• 2006 – Enters into R&D Agreement and Securities Purchase Agreement with Abengoa Bioenergy

• 2006 – Raises approximately $26 million in private transactions

• 2008 –  Enters into non-exclusive license agreement with Codexis, Inc. (biofuels partner of Shell)

• 2009 – Enters into non-exclusive license agreement with Abengoa Bioenergy to use the C1 Platform Technology to produce biofuels, biochemicals and/or power

• 2011 – Enters into research collaboration with Sanofi Pasteur to use the C1 Platform Technology to develop certain vaccines

• 2011 – Enters into non-exclusive research and license agreement with a major company in the animal nutrition industry to use the C1 Platform Technology to develop and produce enzymes for use in animal feed

• 2012 – Enters into non-exclusive research and license agreement with major company in the food industry to produce enzymes to produce certain food products